Additionally, these cells can express functional CD16, enabling antibody-dependent cellular cytotoxicity (ADCC) against tumor cells targeted with antibody-based therapies (Fig. 1), such as trastuzumab, which binds HER2 on breast cancers, and rituximab, which binds CD20 on B-cell lymphomas [1, 49–52]. Here, ERBB2 is linked to breast cancer.